Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma
Open Access
- 28 April 2014
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 4, 90
Abstract
Glioblastoma is the most common primary brain tumor in the adult and carries a poor prognosis with a median survival of only 14 months. Patients with glioblastoma are followed with MRI scans, but this technique has several limitations including low specificity to differentiate between tumor and treatment effect. Development of serum markers could significantly improve the care of glioblastoma patients. We review the current concept of developing YKL-40 as one of the most promising serum markers for glioblastoma, the recent advances on understanding the role of YKL-40 in gliomagenesis, and the promising evidence emerging from preclinical models on using this protein as a target for anti-glioma therapy.Keywords
This publication has 36 references indexed in Scilit:
- Autocrine Endothelin-3/Endothelin Receptor B Signaling Maintains Cellular and Molecular Properties of Glioblastoma Stem CellsMolecular Cancer Research, 2011
- Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomasNeuro-Oncology, 2011
- Association between YKL‐40 and adult primary astrocytomaCancer, 2010
- Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomasJournal of Neuro-Oncology, 2010
- YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas.2010
- YKL-40, a secreted glycoprotein, promotes tumor angiogenesisOncogene, 2009
- Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumorsJournal of Neuro-Oncology, 2009
- YKL-40 and Matrix Metalloproteinase-9 as Potential Serum Biomarkers for Patients with High-Grade GliomasClinical Cancer Research, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma.2002